Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Angina IV: Management01:26

Angina IV: Management

368
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
368
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

346
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
346
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.6K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.6K
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

347
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
347
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

428
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
428
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Coronary Sinus Narrowing for the Treatment of Patients With Angina and Evidence of Microvascular Dysfunction: A Prospective Single-Arm Study.

The Canadian journal of cardiology·2026
Same author

Prognostic Value of Right Atrial Strain in Patients With Moderate-to-Severe Tricuspid Regurgitation.

Journal of the American Heart Association·2026
Same author

Coronary Sinus Reduction for REDUCER-I Patients With Refractory Angina and Angiographically Nonobstructive Coronary Artery Disease.

JACC. Advances·2026
Same author

Safety and Efficacy of Sodium Glucose Cotransporter-2 Inhibitors in Patients With Cancer and Diabetes.

Journal of the American Heart Association·2026
Same author

Long-Term Impact of Prosthesis-Patient Mismatch After Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026
Same author

Neutrophil Gelatinase-Associated Lipocalin for the Assessment of Persistent Renal Dysfunction after Acute Kidney Injury.

Kidney & blood pressure research·2026

Related Experiment Video

Updated: Mar 2, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.1K

[THE CORONARY SINUS REDUCER: A DEVICEBASED THERAPY FOR REFRACTORY ANGINA].

Maayan Konigstein1, Shmuel Banai1

  • 1Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel Aviv University.

Harefuah
|May 23, 2017
PubMed
Summary

The Coronary Sinus (CS) Reducer offers a new treatment for severe coronary artery disease (CAD) patients with refractory angina. This device narrows the CS, improving blood flow to the heart and relieving angina symptoms.

More Related Videos

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

4.3K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.9K

Related Experiment Videos

Last Updated: Mar 2, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.1K
Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

4.3K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.9K

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Biomedical Engineering

Background:

  • Severe coronary artery disease (CAD) poses challenges for revascularization.
  • Refractory angina persists in some CAD patients despite optimal medical therapy.
  • Novel therapeutic strategies are needed for debilitating angina.

Purpose of the Study:

  • To evaluate the Coronary Sinus (CS) Reducer as a treatment for refractory angina.
  • To assess the impact of CS Reducer implantation on myocardial blood flow and angina symptoms.

Main Methods:

  • The CS Reducer, a stainless steel device, is implanted percutaneously into the coronary sinus.
  • The device creates a controlled narrowing of the coronary sinus lumen.
  • Implantation is performed via the right internal jugular vein.

Main Results:

  • The CS Reducer increases coronary venous pressure.
  • This leads to redistribution of blood flow within the myocardium.
  • Improved blood supply to ischemic subendocardial layers is achieved.

Conclusions:

  • The CS Reducer is a novel therapeutic option for patients with severe CAD and refractory angina.
  • The device improves angina symptoms and quality of life.
  • It offers a new approach to managing ischemic heart conditions.